Audience:
Neuropsychiatric healthcare professionals Janssen Pharmaceutica and FDA revised
the WARNINGS section of the prescribing information for Risperdal (risperidone),
indicated for the treatment of schizophrenia. Cerebrovascular adverse events (e.g.,
stroke, transient ischemic attack), including fatalities, were reported in patients
in trials of risperidone in elderly patients with dementia-related psychosis.
In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular
adverse events in patients treated with risperidone compared to patients treated
with placebo. RISPERDAL has not been shown to be safe or effective in the treatment
of patients with dementia-related psychosis.
*Many cases are in
the investigative stages, but make a complaint now and your case can be evaluated.
Find out if you are owed money for damages and injury?